First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors | Zendy

John H. Strickler | Zendy; Colin D. Weekes | Zendy; John Nemunaitis | Zendy; Ramesh K. Ramanathan | Zendy; Rebecca S. Heist | Zendy; Daniel Morgensztern | Zendy; Eric Angevin | Zendy; Todd M. Bauer | Zendy; Huibin Yue | Zendy; Monica Motwani | Zendy; Apurvasena Parikh | Zendy; Edward B. Reilly | Zendy; Daniel Afar | Zendy; Louie Naumovski | Zendy; Karen Kelly | Zendy

Open Access

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors

Author(s) -

John H. Strickler,

Colin D. Weekes,

John Nemunaitis,

Ramesh K. Ramanathan,

Rebecca S. Heist,

Daniel Morgensztern,

Eric Angevin,

Todd M. Bauer,

Huibin Yue,

Monica Motwani,

Apurvasena Parikh,

Edward B. Reilly,

Daniel Afar,

Louie Naumovski,

Karen Kelly

Publication year - 2018

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2018.78.7697

Subject(s) - medicine , antibody drug conjugate , conjugate , drug , antibody , solid tumor , oncology , pharmacology , cancer research , monoclonal antibody , cancer , immunology , mathematical analysis , mathematics

This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody-drug conjugate of the anti-c-Met monoclonal antibody ABT-700 and monomethyl auristatin E.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research